Literature DB >> 32292128

Patient-Reported Quality-of-Life Outcome Measures in the Thyroid Cancer Population.

Eve M Roth1, Carrie C Lubitz1,2,3, John Shannon Swan1,3,4, Benjamin C James1,5.   

Abstract

Background: There is an escalating worldwide population of thyroid cancer (TC) survivors. In addition to conventional metrics of quality of care, quality-of-life (QoL) assessment in TC patients is imperative. TC survivors face unique impediments to health-related quality of life (HRQoL), including thyroid-specific symptoms and exposure to disease-related stressors-including fear of recurrence and financial toxicity-over a prolonged survival period. Survey instruments currently used to assess HRQoL in TC survivors may be insufficient to accurately capture the burden of disease in this population. We aimed to identify the HRQoL instruments in the literature, which have been applied in the TC survivor population, and to present the psychometric properties of the scales and indexes that have been used. We hypothesized that few instruments have shown evidence of validity in this population. Summary: Of the 927 articles identified by search criteria, only 28 studies using 15 HRQoL instruments met inclusion criteria. Of the 15 HRQoL instruments identified, 9 were psychometric health status instruments and 6 were preference-based indexes, but none had been validated in the TC survivor population. While the majority of reviewed studies demonstrated impaired psychological and emotional well-being in TC survivors, these findings were not uniformly demonstrated across studies, and the longevity of the impact of TC on HRQoL was variably reported. Conclusions: Discrepancies in the literature regarding the impact of TC survivorship on HRQoL emphasize the challenges of accurately assessing patient perspectives, reinforcing the importance of using well-constructed instruments to measure patient-reported outcomes in the target population. Care providers involved in the treatment of TC survivors should be aware of longitudinal effects on HRQoL, especially pertaining to chronic psychological debilitation. Further development and rigorous validation of TC-specific instruments will allow for better data gathering and understanding of the barriers to achieving high long-term HRQoL in TC survivors throughout their long postsurvival course.

Entities:  

Keywords:  patient-reported outcomes; quality of life; thyroid cancer

Year:  2020        PMID: 32292128      PMCID: PMC7583324          DOI: 10.1089/thy.2020.0038

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  57 in total

1.  The quality of lives: 1,525 voices of cancer.

Authors:  B R Ferrell
Journal:  Oncol Nurs Forum       Date:  1996-07       Impact factor: 2.172

2.  Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.

Authors:  K H Dow; B R Ferrell; C Anello
Journal:  Thyroid       Date:  1997-08       Impact factor: 6.568

3.  Prognostic value of pre- and post-treatment health-related quality of life in predicting survival of patients with brain metastases.

Authors:  Erin Wong; Leigha Rowbottom; May Tsao; Liying Zhang; Rachel McDonald; Cyril Danjoux; Elizabeth Barnes; Stephanie Chan; Edward Chow
Journal:  CNS Oncol       Date:  2017-04

4.  A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases.

Authors:  Katy Gallop; Cicely Kerr; Stacey Simmons; Bryan McIver; Ezra E W Cohen
Journal:  Qual Life Res       Date:  2014-08-09       Impact factor: 4.147

5.  Quality of life in differentiated thyroid cancer.

Authors:  Charlotte McIntyre; Thomas Jacques; Fausto Palazzo; Kate Farnell; Neil Tolley
Journal:  Int J Surg       Date:  2017-12-26       Impact factor: 6.071

6.  The EORTC module for quality of life in patients with thyroid cancer: phase III.

Authors:  Susanne Singer; Susan Jordan; Laura D Locati; Monica Pinto; Iwona M Tomaszewska; Cláudia Araújo; Eva Hammerlid; E Vidhubala; Olga Husson; Naomi Kiyota; Christine Brannan; Dina Salem; Eva M Gamper; Juan Ignacio Arraras; Georgios Ioannidis; Guy Andry; Johanna Inhestern; Vincent Grégoire; Lisa Licitra
Journal:  Endocr Relat Cancer       Date:  2017-02-21       Impact factor: 5.678

7.  Health-related quality of life, fear of recurrence, and emotional distress in patients treated for thyroid cancer.

Authors:  S N Rogers; V Mepani; S Jackson; D Lowe
Journal:  Br J Oral Maxillofac Surg       Date:  2017-06-23       Impact factor: 1.651

8.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

9.  Quality of life of patients undergoing surgical treatment of head and neck malignancy.

Authors:  S Lloyd; P Devesa-Martinez; D J Howard; V J Lund
Journal:  Clin Otolaryngol Allied Sci       Date:  2003-12

10.  The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients.

Authors:  Carrie C Lubitz; Julie A Sosa
Journal:  Cancer       Date:  2016-08-12       Impact factor: 6.860

View more
  3 in total

1.  Machine learning-based random forest for predicting decreased quality of life in thyroid cancer patients after thyroidectomy.

Authors:  Yong Hong Liu; Jian Jin; Yun Jiang Liu
Journal:  Support Care Cancer       Date:  2021-11-16       Impact factor: 3.603

2.  Mental Health in Postoperative Thyroid Patients During the COVID-19 Pandemic.

Authors:  Shijie Yang; Xiequn Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

3.  Impact of Nasolacrimal Dysfunction in Thyroid Cancer Survivors.

Authors:  Jacqueline Jonklaas
Journal:  Thyroid       Date:  2022-03-22       Impact factor: 6.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.